BRIEF-FDA Approves Genentech's Tecentriq Plus Lurbinectedin As First-Line Maintenance Therapy For Extensive-Stage Small Cell Lung Cancer

Oct 2 (Reuters) – Roche Holding AG: * FDA APPROVES GENENTECH’S TECENTRIQ PLUS LURBINECTEDIN AS FIRST-LINE MAINTENANCE THERAPY FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)